$TRVI News
Last published 2d ago
- 2d agoTRVITrevi Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoTRVITrevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireInitiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough
- 2d agoTRVITREVI THERAPEUTICS, INC. 3Q 2026 FINANCIAL RESULTS - TREVI THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Trevi Therapeutics 3rd Quarter 2026 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. After today's presentation, there wil
- 1w agoTRVITrevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026GlobeNewswireNEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the
- 2w agoTRVITrevi Therapeutics to Participate in Stifel's 2026 Healthcare ConferenceGlobeNewswireNEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the
- 4w agoTRVITrevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingGlobeNewswireNEW HAVEN, Conn., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of
- 1mo agoTRVITrevi Therapeutics - 1773846 - TREVI THERAPEUTICS INCEarnings Call TranscriptsAll right. Good afternoon, everyone. Thanks for being here. We're very excited to have Jennifer and James from Trevi here with us for this session of the Morgan Stanley Global Healthcare Conference. I'm just going to get
- 1mo agoTRVITrevi Therapeutics - 1773846 - TREVI THERAPEUTICS INCEarnings Call TranscriptsAll right. Good afternoon, everyone. Thanks for being here. We're very excited to have Jennifer and James from Trevi here with us for this session of the Morgan Stanley Global Healthcare Conference. I'm just going to get
- 2mo agoTRVITrevi Therapeutics to Participate in Upcoming September ConferencesGlobeNewswireNEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the
- 3mo agoTRVITrevi Therapeutics, Inc. 2Q 2026 Financial Results - TREVI THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Trevi Therapeutics Second Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After today's presentation, there will be an opportunity to as
- 3mo agoTRVITrevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireInitiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b
- 3mo agoTRVITrevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026GlobeNewswireNEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the
- 3mo agoTRVITrevi Therapeutics to Participate in Upcoming August ConferencesGlobeNewswireNEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the
- 4mo agoTRVITrevi Therapeutics Announces Upcoming June and July Event ScheduleGlobeNewswireNEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the
- 6mo agoTRVITrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireCompleted follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline
- 6mo agoTRVITrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceGlobeNewswirePrimary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough
- 6mo agoTRVITrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026GlobeNewswireNEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 6mo agoTRVITrevi Therapeutics to Participate in Upcoming May EventsGlobeNewswireNEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 6mo agoTRVITrevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewswireNEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 6mo agoTRVITrevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockGlobeNewswireNEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 6mo agoTRVITrevi Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireNEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 7mo agoTRVITrevi Therapeutics to Participate in Upcoming EventsGlobeNewswireNEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 8mo agoTRVITrevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026GlobeNewswireNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 8mo agoTRVITrevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic CoughGlobeNewswireThe Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of 2026, with the
- 8mo agoTRVITrevi Therapeutics to Participate in Upcoming March ConferencesGlobeNewswireNEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
- 8mo agoTRVITrevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireNEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the
- 9mo agoTRVITrevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)PR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the ...
- 10mo agoTRVITrevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare ConferencePR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 11mo agoTRVITrevi Therapeutics Announces Appointment of David Hastings as Chief Financial OfficerPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 12mo agoTRVITrevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025PR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Participate in Stifel 2025 Healthcare ConferencePR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual MeetingPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the ...
- 1y agoTRVITrevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025PR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoTRVITrevi Therapeutics to Participate in Upcoming September ConferencesPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTRVITrevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025PR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Participate in Upcoming August ConferencesPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and MetabolismPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics Announces Proposed Public Offering of Common StockPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughPR NewswireTrevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Participate in Upcoming June ConferencesPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic CoughPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesPR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
- 1y agoTRVITrevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025PR NewswireTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...